Author:
Kowall Bernd,Maier Gregor,Rathmann Wolfgang
Reference14 articles.
1. Glucogon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes;Wang;JAMA Netw Open,2024
2. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis;Yao;BMJ,2024
3. B. Lauby-Secretan, C. Scoccianti, D. Loomis, Y. Grosse, F. Bianchini, and K. Straif, “Body fatness and cancer — viewpoint of the IARC Working Group,” New England Journal of Medicine, vol. 375, no. 8. Massachusetts Medical Society, pp. 794–798, Aug. 25, 2016. doi:https://doi.org/10.1056/nejmsr1606602.
4. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis;Soranna;Oncologist,2012
5. Metformin and the risk of cancer: time-related biases in observational studies;Suissa;Diabetes Care,2012